Lilly bets on Seamless, delving further into genetic medicine for hearing loss

Eli Lilly expands work on gene therapies for hearing

Today's biotech news includes the Regenxbio trials halted after a brain tumor discovery, Lilly expanding gene therapies for hearing, and more

Lilly bets on Seamless, delving further into genetic medicine for hearing loss

The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge treatments the company is developing for hearing disorders.

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

New York, Jan 28, 2026, 12:03 ET — Regular session Eli Lilly and Company shares dipped roughly 2.4% to $1,015.05 on Wednesday, following a close of $1,039.51 the day before. Intraday, the stock fluctuated between $1,012.09 and $1,038.96. Traders are processing Lilly’s latest move into genetic medicines. The company inked a deal with Seamless Therapeutics valued at up to $1.12 billion to develop and commercialize gene-editing treatments for heari…

Eli Lilly outlays $1.12bn for hearing loss gene therapy partnership - Pharmaceutical Technology

Lilly and German biotech Seamless Therapeutics will develop recombinase-based treatments for hearing loss.

Lilly, Seamless Ink Up-to-$1.12B Hearing Loss Collaboration

Eli Lilly plans to expand its hearing loss therapy pipeline by collaborating with Seamless Therapeutics to apply the company’s next-generation gene-editing approach, based on programmable recombinases, to develop and commercialize hearing loss treatments—a deal that could generate more than $1.12 billion for the German startup. Under a strategic global research collaboration and licensing agreement with Lilly, Seamless has agreed to design and p…